title: Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
authors.forename: Basri
authors.initials: B
authors.lastname: Amasyali
authors.forename: Turgay
authors.initials: T
authors.lastname: Celik
authors.forename: Atila
authors.initials: A
authors.lastname: Iyisoy
authors.forename: Ayhan
authors.initials: A
authors.lastname: Kilic
authors.forename: Ersoy
authors.initials: E
authors.lastname: Isik
mesh_terms: D000284:Administration, Oral; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation; D001241:Aspirin / Q000008:administration & dosage; D000077407:Cilostazol; D000077144:Clopidogrel; D023903:Coronary Restenosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin